Form 4: Recursion Pharmaceuticals Director Elaine Sun Granted Equity Awards

Elaine Sun, a Director at Recursion Pharmaceuticals, Inc. (RXRX), was granted 11,008 restricted stock units and options to purchase 22,016 shares of Class A Common Stock as part of the company's Outside Director Compensation Policy.

Summary

• Elaine Sun, a Director of Recursion Pharmaceuticals, Inc. (RXRX), received a grant of 11,008 restricted stock units (RSUs) on June 18, 2025.
• These RSUs were granted at a price of $0 and are part of the Issuer's Outside Director Compensation Policy.
• The RSUs will vest on the earlier of June 18, 2026, or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, contingent on Ms. Sun's continued service.
• Following this transaction, Ms. Sun beneficially owns 47,557 shares of Class A Common Stock directly.
• Additionally, Ms. Sun was granted stock options to purchase 22,016 shares of Class A Common Stock on June 18, 2025.
• The exercise price for these stock options is $5.11 per share, and they were granted at a price of $0.
• These options will vest and become exercisable on the earlier of June 18, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders, also subject to her continued service.
• The stock options have an expiration date of June 18, 2035.
• Following this transaction, Ms. Sun beneficially owns 22,016 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While it's a routine compensation event, it signifies continued director commitment and aligns interests with shareholders, which is generally viewed favorably. The slight dilution from future vesting is a minor negative.

Positives

• The grant of restricted stock units and stock options aligns the director's interests with long-term shareholder value through equity ownership.
• The compensation policy for outside directors helps attract and retain experienced board members.

Negatives

• The issuance of new equity awards, upon vesting and exercise, can lead to a slight dilution for existing shareholders.

Risks

• The vesting of both RSUs and stock options is contingent upon the reporting person's continued service to the Issuer, meaning the awards could be forfeited if service ceases before vesting.

Future Outlook

The document primarily details a past equity grant and its future vesting schedule, not providing broader forward-looking statements or guidance on company performance.

Industry Context

This Form 4 filing reflects a standard practice in the biotechnology and pharmaceutical industry where non-employee directors receive equity compensation as part of their remuneration package, aligning their interests with the company's long-term performance.

Comparison to Industry Standards

• The grant of equity awards (RSUs and stock options) to outside directors is a common compensation practice across publicly traded companies, including those in the biotech sector, such as Moderna (MRNA) or BioNTech (BNTX), which often use similar mechanisms to incentivize and retain board members.
• The vesting schedule tied to continued service is standard for such equity grants, comparable to practices seen at companies like Vertex Pharmaceuticals (VRTX) or Gilead Sciences (GILD) for their non-executive directors.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor dilution upon vesting and exercise of the equity awards, but also benefits from aligning director incentives with long-term company performance.
• Employees: No direct impact mentioned, but reflects standard corporate compensation practices.

Next Steps

• The restricted stock units and stock options are scheduled to vest on the earlier of June 18, 2026, or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service.

Key Dates

Recommendation

Keywords

Recursion Pharmaceuticals, RXRX, SEC Form 4, Restricted Stock Units, Stock Options, Director Compensation, Equity Grant, Beneficial Ownership, Insider Transaction